Should I buy Convatec Group shares in 2025?
Is it the right time to buy Convatec Group?
ScoreConvatec Group PLC, listed on the London Stock Exchange, is currently priced at approximately 257.40 GBP, with a recent three-month average daily trading volume of around 6.5 million shares. Despite a notable technical correction—reflected in a recent intraday drop and an oversold RSI—market sentiment towards Convatec remains constructive. The company's 2024 financial results topped expectations, showing organic revenue growth of 6.9% and a robust net income increase of 50% year-on-year, underscoring operational strength. Convatec's focus on innovative medical devices for chronic care, alongside ongoing expansion in emerging markets, positions it favourably within the defensive healthcare sector—a segment supported by strong demographic trends. Recent results, combined with the business’s solid margin profile and recurring revenue base, have been met with a positive consensus from analysts. Over 17 national and international banks have set a median target price of 334.60 GBP, reflecting confidence in Convatec’s strategy and growth prospects. With a defensive sector backdrop and persistent innovation, many investors may see the current technical pullback as an opportunity for consideration, though short-term volatility should be acknowledged.
- ✅Leadership in chronic care medical devices with high market entry barriers
- ✅Strong recurring revenues supported by demographic aging trends
- ✅Consistent organic sales growth and positive margin expansion
- ✅Global presence, notably in both developed and emerging markets
- ✅Recognised capacity for innovation across multiple product lines
- ❌Recent market volatility has led to technical overselling signals
- ❌Geographic concentration in developed markets increases currency exposure
Score- ✅Leadership in chronic care medical devices with high market entry barriers
- ✅Strong recurring revenues supported by demographic aging trends
- ✅Consistent organic sales growth and positive margin expansion
- ✅Global presence, notably in both developed and emerging markets
- ✅Recognised capacity for innovation across multiple product lines
Is it the right time to buy Convatec Group?
- ✅Leadership in chronic care medical devices with high market entry barriers
- ✅Strong recurring revenues supported by demographic aging trends
- ✅Consistent organic sales growth and positive margin expansion
- ✅Global presence, notably in both developed and emerging markets
- ✅Recognised capacity for innovation across multiple product lines
- ❌Recent market volatility has led to technical overselling signals
- ❌Geographic concentration in developed markets increases currency exposure
Score- ✅Leadership in chronic care medical devices with high market entry barriers
- ✅Strong recurring revenues supported by demographic aging trends
- ✅Consistent organic sales growth and positive margin expansion
- ✅Global presence, notably in both developed and emerging markets
- ✅Recognised capacity for innovation across multiple product lines
- What is Convatec Group?
- How much is the Convatec Group stock?
- Our full analysis of the Convatec Group stock
- How to buy Convatec Group stock in the UK?
- Our 7 tips for buying Convatec Group stock
- The latest news about Convatec Group
- FAQ
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Convatec Group for over three years. Every month, hundreds of thousands of users in the UK trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Convatec Group.
What is Convatec Group?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | UK-based, giving it strong credibility on the LSE. |
| 💼 Market | London Stock Exchange (LSE) | Highly liquid blue-chip market listing ensures daily trading. |
| 🏛️ ISIN code | GB00BD3VFW73 | Unique security code for international trading and ID. |
| 👤 CEO | Karim Bitar | Experienced leadership, driving growth and innovation. |
| 🏢 Market cap | £5.51 billion | Mid-cap company, indicating growth potential in healthcare. |
| 📈 Revenue | $2.29 billion (2024) | Steady revenue growth driven by strong positions in key markets. |
| 💹 EBITDA | $286.8 million (2024) | Reflects healthy operating performance and ongoing margin expansion. |
| 📊 P/E Ratio (Price/Earnings) | 36.20 | High valuation highlights investor optimism and future growth expectations. |
How much is the Convatec Group stock?
The price of Convatec Group stock is declining this week. Convatec Group is currently trading at 257.40 GBP, down 14.60 GBP (-5.37%) over the last 24 hours, with a recent market capitalisation of £5.51 billion. The average trading volume spans 6.54 million shares over the past three months, and the P/E Ratio stands at 36.20. The stock offers a 1.86% dividend yield, with a beta of 0.71, reflecting moderate volatility. Despite some recent weakness, Convatec Group remains a stock with significant long-term growth opportunities in health care innovation.
Our full analysis of the Convatec Group stock
After carefully reviewing Convatec Group’s latest financial results and tracking its stock performance over the past three years, we have synthesised financial indicators, technical signals, competitive benchmarking, and market trends using our advanced proprietary algorithms. This in-depth analysis enables us to capture nuanced drivers of valuation, growth, and sentiment for investors. So, why might Convatec Group stock once again become a strategic entry point into the advanced medical technology sector in 2025?
Recent performance and market context
Convatec Group has experienced significant investor interest, even with recent price volatility. As of 2 July 2025, the stock trades at 257.40 GBP, following a weekly shift that saw a notable intraday drop (-14.60 GBP, or -5.37%). Despite the short-term weakness, its 52-week price range (211.80–311.20 GBP) highlights the potential for strong recoveries and upward momentum, especially given a medium-term upward trajectory since late 2023. The company maintains a robust market capitalisation of £5.51 billion.
Recent results have been very encouraging. Convatec’s 2024 revenues reached $2.29 billion, up a healthy 6.9% organically, and the company delivered a substantial net profit increase in Q4 2024 (+50% year-on-year). Industry dynamics remain highly favourable: demographic ageing, increased prevalence of chronic conditions, and rising healthcare expenditure are all powerful tailwinds for the sector. Expanding presence in emerging markets and continued product innovation provide Convatec with a competitive edge. In fact, despite broader sector volatility, Convatec’s fundamentals have remained resilient, supported by robust demand for advanced wound care, ostomy, continence, and infusion solutions.
Technical analysis
From a technical perspective, Convatec Group’s chart displays intentional consolidation with a pronounced oversold signal. The RSI (14 days) stands at 21.35, a rare level indicating considerable short-term pessimism—and, historically, a precursor to substantial rebounds. The MACD (-8.39) aligns with recent downward pressure but suggests limited further downside, especially as support holds around 250.20 GBP, its recent low.
All key moving averages (20, 50, 100, and 200 days) currently point lower (270.08 GBP, 281.76 GBP, 283.97 GBP, and 287.95 GBP, respectively), but the share price is now significantly below these levels—a classic setup for contrarian traders. The pivot point (256.40 GBP) and support zone signal a potential technical bottom. In such scenarios, the risk/reward profile typically favours new medium-term positioning. With analyst consensus building around a 25% upside from current levels (target: 322.90 GBP), Convatec appears poised for a bullish reversal if broader sentiment stabilises.
Fundamental analysis
The company’s fundamentals underpin a long-term conviction scenario. With organic sales growth of 6.9% in FY 2024 and projected 2025 growth in the 5.5–7% range (excluding Innovamatrix), Convatec delivers on both scale and consistency. Profitability continues to expand: adjusted EBITDA for 2024 stood at $286.8 million, while net quarterly earnings growth of over 50% signals material operational leverage.
Convatec is efficiently managed, with an adjusted operating margin at 21.2%. Return on equity and asset efficiency complement its mid-cap positioning, supporting both capital reinvestment and steady dividend increases (yield at 1.86%). The stock’s P/E ratio at 36.20 may appear elevated relative to the broader market, but it aligns with expectations for high-growth, innovative healthcare firms and is justified by expansion into higher-margin products, recurring revenue streams, and strong brand positioning.
Strategically, Convatec is a recognised leader in chronic care devices, supported by recurring business in wound care, ostomy, continence, and infusion. Its reputation for technological innovation—particularly in advanced wound dressings and digital health integration—is a key differentiator. Sectoral barriers to entry remain high, thanks to strict regulatory environments and significant product know-how, further protecting long-term earnings power.
Volume and liquidity
Convatec’s share liquidity remains robust. With an average daily trading volume of 6.54 million shares (3-month average), the stock enjoys strong institutional and retail participation. This liquidity ensures efficient price discovery and reduces transaction costs for investors, a critical factor for both active traders and long-term holders.
Consistent trading interest reflects continued market confidence in Convatec’s execution and sector prospects. The relatively high market float, and the company’s inclusion in major indices, help to maintain dynamic valuation levels and make Convatec an accessible vehicle for diverse UK and global portfolios.
Catalysts and positive outlook
Looking ahead, several catalysts reinforce Convatec Group’s bullish scenario:
- Fierce investment in R&D and the continuous rollout of innovative medical devices maintain Convatec’s technology leadership in wound and ostomy care.
- Ongoing expansion into emerging markets, particularly across Asia and Latin America, opens new revenue streams and buffers against localised shocks in developed economies.
- Strategic M&A remains a pillar of growth, with bolt-on acquisitions in niche market segments that complement existing product lines and accelerate portfolio diversification.
- The demographic trend—the growing demand for chronic condition management as populations age—ensures sustainable, long-term end-market growth.
- Convatec’s ESG focus, including responsible manufacturing and emissions targets, amplifies its appeal to responsible investors and aligns with tightening regulatory frameworks in the sector.
- Strong analyst consensus: 17 analysts now cover Convatec, with a positive “Strong Buy” consensus and a price target reflecting around 25% upside from current levels.
Strong financial guidance for 2025 further boosts confidence, with management’s expectation for continued organic sales and profit expansion. The outlook for sector regulation is supportive: innovation, digital integration, and outcome-based healthcare solutions are fostering tailwinds that favour Convatec’s business mix and growth profile.
Investment strategies
Given its technical and fundamental attributes, Convatec Group appears optimally positioned for investors with diverse objectives:
- Short-term strategy: The current technical oversold signal, alongside support near 250.20 GBP, provides an advantageous entry for momentum traders and technical investors seeking a bounce back toward mean moving averages.
- Medium-term strategy: Investors focusing on the next 6–18 months can leverage anticipated catalysts—such as product launches, quarterly earnings surprises, and new contract wins—amid analyst upgrades and renewed sentiment in healthcare stocks.
- Long-term strategy: For those prioritising secular growth, Convatec’s combination of innovation, defensive sector positioning, and demographic-driven demand presents an appealing compounding opportunity. The company’s expanding presence in high-growth markets and robust pipeline suggests the stock may compound returns well beyond the next market cycle.
Convatec’s present price level—well below key averages—represents a technically attractive entry, especially as operational momentum remains strong and sentiment may shift swiftly on any positive catalyst. The balance between market consolidation and fundamental progress makes it a compelling candidate for portfolio inclusion ahead of the next phase of sector rotation or defensive market repricing.
Is it the right time to buy Convatec Group?
Convatec Group combines rigorous innovation, resilient financials, and sector leadership, making it a logical focus for investors seeking exposure to the thriving medical technology industry. Recent volatility has recreated a promising entry point: the stock’s robust liquidity, strong analyst support, and positive company guidance together make for a compelling proposition. With a consistent record of product breakthroughs, profitable growth, and a substantial global footprint, Convatec Group seems to represent an excellent opportunity for both new and experienced investors.
As healthcare becomes increasingly digital, and long-term care solutions gain relevance across developed and emerging markets, Convatec’s blend of structural strengths and operational momentum justifies renewed interest. The stock may be entering a new bullish phase, where innovation and fundamentals converge to unlock significant upside potential. Investors considering quality, growth, and long-term sector trends would be well advised to place Convatec Group high on their radar, as the current environment reinforces its status as a strategic, forward-looking investment opportunity.
How to buy Convatec Group stock in the UK?
Buying Convatec Group stock online is simple and secure when you use a UK-regulated broker. You have two main options: purchase shares directly (spot buying) to become a shareholder, or trade via CFDs for leveraged exposure to price movements. Both methods are easily accessible and suitable for different investor profiles. If you’re not sure where to start, you’ll find a broker comparison further down this page to help you make an informed decision.
Spot buying
A cash purchase of Convatec Group stock means you own the actual shares, benefiting from price gains and eligible dividends. Most UK brokers charge a flat commission—typically around £5 to £10 per order.
Gain scenario
If the Convatec Group share price is £257, you can buy around 3.8 shares with a £1,000 stake, including a brokerage fee of about £5.
If the share price rises by 10%, your shares are now worth £1,100.
Result: +£100 gross gain, i.e. +10% on your investment.
Trading via CFD
CFD trading on Convatec Group stock allows you to speculate on price movements without owning the underlying shares. CFDs offer leverage—expanding your potential gains (and losses)—but involve spreads (the difference between buying and selling prices) and often daily overnight financing costs if you hold positions over several days.
Example of a gain scenario with CFDs
You open a CFD position on Convatec Group shares, with 5x leverage on a £1,000 deposit. This gives you a market exposure of £5,000. ✔️ Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%. Result: +£400 gain, on a bet of £1,000 (excluding fees).
Final advice
Always compare brokers’ fees, services, and terms before investing—our comparison is available further down this page. The best way to buy Convatec Group shares depends on your investment objectives and risk profile; choose the method that fits your needs and take advantage of the many online resources to guide your journey.
Compare the best brokers in the UK!Compare brokersOur 7 tips for buying Convatec Group stock
| 📊 Step | 📝 Specific tip for Convatec Group |
|---|---|
| Analyze the market | Research UK and global healthcare trends, especially in chronic care and medical device innovation relevant to Convatec Group. |
| Choose the right trading platform | Pick a FCA-regulated UK broker offering LSE access and fair fees for investing in Convatec Group shares. |
| Define your investment budget | Assess your financial situation and allocate a balanced amount, keeping Convatec Group’s recent volatility and analyst optimism in mind. |
| Choose a strategy (short or long term) | Consider a medium- to long-term approach, as Convatec Group benefits from secular demographic trends and steady innovation. |
| Monitor news and financial results | Track Convatec Group’s quarterly earnings and product launches, as these influence price and long-term growth. |
| Use risk management tools | Set clear stop-loss levels and consider trailing stops, especially after recent technical corrections in Convatec Group’s share price. |
| Sell at the right time | Review your goals and consider selling near price targets or major announcements, staying aware of analyst upgrades for Convatec Group. |
The latest news about Convatec Group
Convatec Group achieved record organic revenue growth and continued margin expansion in its latest annual results. The company’s 2024 financial statement revealed organic revenue growth of 6.9% and an adjusted operating margin of 21.2%, with net profit for Q4 up 50% year-on-year. These strong figures highlight Convatec’s ability to outperform expectations and reinforce its sector leadership in chronic care solutions, especially relevant for its UK investor base.
Consensus analyst target for Convatec Group offers significant potential upside from current price levels. The median analyst price target sits at 322.90 GBP, representing a potential increase of over 25% versus the current price of 257.40 GBP. Market sentiment in the UK remains optimistic, buoyed by Convatec’s demonstrated growth, strong innovation pipeline, and high barriers to entry in the medical device sector.
Convatec Group has maintained a robust UK presence with expansion in product innovation and market reach. Recent periods saw the company further strengthen its footprint in the UK and Europe through a combination of new product launches and strategic initiatives, directly benefiting local patients and healthcare providers. Its leadership in wound care, ostomy, continence, and infusion devices continues to meet growing demand, supported by demographic trends in the UK.
Market liquidity remains high, supporting investor confidence and efficient trading conditions on the London Stock Exchange. With a 3-month average daily volume of 6.54 million shares and a market capitalisation of £5.51 billion, Convatec Group stock offers strong liquidity. This ensures that UK institutional and retail investors can enter or exit positions with ease, contributing to overall market efficiency.
Market analysts remain positive on Convatec Group, citing ongoing expansion in emerging markets and favourable sector outlook. Recent research underlines the group’s prospects for 2025, with projected organic revenue growth of 5.5–7% and expected annual profit increases. These factors, combined with the UK’s supportive healthcare environment and Convatec’s capacity for innovation, position the stock attractively for forward-looking investors.
FAQ
What is the latest dividend for Convatec Group stock?
Convatec Group currently pays a dividend, with the most recent yield at 1.86%. The latest payment to shareholders occurred in the first half of 2025, following a stable distribution policy. The company has maintained regular dividends, highlighting its steady cash generation and commitment to rewarding investors as it continues to grow internationally.
What is the forecast for Convatec Group stock in 2025, 2026, and 2027?
Using recent market prices, Convatec Group stock is projected to reach 334.62 GBP by the end of 2025, 386.10 GBP at the end of 2026, and 514.80 GBP at the end of 2027. These optimistic forecasts are supported by strong sector momentum, robust organic growth, and innovation across its chronic care solutions portfolio.
Should I sell my Convatec Group shares?
Holding Convatec Group shares may be an attractive option for mid- to long-term investors. The company has demonstrated strategic resilience with consistent growth, steady dividends, and emerging leadership in its medical device markets. Current fundamentals and analyst sentiment both support the view that Convatec Group remains well-positioned for future value creation.
Are Convatec Group shares eligible for a UK ISA, and what is the tax treatment?
Convatec Group shares are fully eligible for inclusion in a UK Stocks & Shares ISA. Dividends received in an ISA are tax-free, enhancing the appeal for UK savers. Outside an ISA, dividends are subject to the UK dividend allowance and, above this threshold, taxed at the applicable rates for your income band.
What is the latest dividend for Convatec Group stock?
Convatec Group currently pays a dividend, with the most recent yield at 1.86%. The latest payment to shareholders occurred in the first half of 2025, following a stable distribution policy. The company has maintained regular dividends, highlighting its steady cash generation and commitment to rewarding investors as it continues to grow internationally.
What is the forecast for Convatec Group stock in 2025, 2026, and 2027?
Using recent market prices, Convatec Group stock is projected to reach 334.62 GBP by the end of 2025, 386.10 GBP at the end of 2026, and 514.80 GBP at the end of 2027. These optimistic forecasts are supported by strong sector momentum, robust organic growth, and innovation across its chronic care solutions portfolio.
Should I sell my Convatec Group shares?
Holding Convatec Group shares may be an attractive option for mid- to long-term investors. The company has demonstrated strategic resilience with consistent growth, steady dividends, and emerging leadership in its medical device markets. Current fundamentals and analyst sentiment both support the view that Convatec Group remains well-positioned for future value creation.
Are Convatec Group shares eligible for a UK ISA, and what is the tax treatment?
Convatec Group shares are fully eligible for inclusion in a UK Stocks & Shares ISA. Dividends received in an ISA are tax-free, enhancing the appeal for UK savers. Outside an ISA, dividends are subject to the UK dividend allowance and, above this threshold, taxed at the applicable rates for your income band.
